References
- AbelsonMBGomesPJOlopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosingExpert Opin Drug Metab Toxicol20084445346118433347
- SánchezMCParra FernándezBMatheuVAllergic conjunctivitisJ Investig Allergol Clin Immunol201121Suppl 2119
- RosarioNBieloryLEpidemiology of allergic conjunctivitisCurr Opin Allergy Clin Immunol20111147147621785348
- SinghKAxelrodSBieloryLThe epidemiology of ocular and nasal allergy in the United States, 1988–1994J Allergy Clin Immunol20101264778.e6783.e620920769
- UchioETreatment of allergic conjunctivitis with olopatadine hydrochloride eye dropsClin Ophthalmol20082352553119668750
- McGillJIA review of the use of olopatadine in allergic conjunctivitisInt Ophthalmol200425317117915847317
- SharifNAXuSXMillerSTGamacheDAYanniJMCharacterization of the ocular anti-allergic and antihistaminic activity of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseasesJ Pharmacol Exp Ther19962783125212618819509
- YanniJMStephensDJMillerSTThe in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agentJ Ocul Pharmacol Ther19961243894008951675
- YanniJMWeimerLKSharifNAXuSXGamacheDASpellmanJMInhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugsArch Ophthalmol1999117564364710326962
- GreinerJVEdwards-SwansonKIngermanAEvaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%Clin Ophthalmol20115879321339800
- AckermanSD’AmbrosioFJrGreinerJVVillanuevaLCiolinoJBHollanderDAA multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge modelJ Asthma Allergy20136435224109191
- IyerGRCasonMMWombleSWLiGChastainJEOcular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbitsJ Ocul Pharmacol Ther201531420421025775192
- AbelsonMBGomesPJVogelsonCTClinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental studyClin Ther20042681237124815476905
- BerdyGJSpanglerDLBenschGBerdySSBrusattiRCA comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge modelClin Ther200022782683310945509
- SpanglerDLBenschGBerdyGJEvaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge modelClin Ther20012381272128011558863
- VogelsonCTAbelsonMBPasquineTPreclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administrationAllergy Asthma Proc2004251697515055565
- TorkildsenGNarvekarABergmannMEfficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge modelClin Ophthalmol201591703171326392751
- McLaurinENarvekarAGomesPAdewaleATorkildsenGPhase 3 randomized double-masked study of efficacy and safety of once-daily 0.77% olopatadine hydrochloride ophthalmic solution in subjects with allergic conjunctivitis using the conjunctival allergen challenge modelCornea201534101245125126266427
- AbelsonMBChambersWASmithLMConjunctival allergen challenge: a clinical approach to studying allergic conjunctivitisArch Ophthalmol1990108184882297337
- MahFSRosenwasserLJTownsendWDGreinerJVBenschGEfficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challengeCurr Med Res Opin20072361445145217559743